Literature DB >> 1697502

Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line.

E Chu1, S Zinn, D Boarman, C J Allegra.   

Abstract

The antiproliferative effects and pharmacological interactions of 5-fluorouracil (5-FU) in combination with gamma interferon (IFN-gamma) were determined against the human colon carcinoma H630 cell line in vitro. H630 was 9-fold more resistant to 5-FU, as compared to a relatively sensitive human colon line (C1). IFN-gamma showed modest antiproliferative activity against the H630 line, with a 50% inhibitory concentration of 440 units/ml. Simultaneous treatment of H630 with subinhibitory concentrations of IFN-gamma and 5-FU produced a significant enhancement of the 5-FU-associated growth inhibition. The growth-inhibitory activity of the combination against H630 was prevented by the addition of 20 microM thymidine. Thymidylate synthase (TS) activity was measured by both the 5-fluoro-2'-deoxyuridine-5'-monophosphate binding and catalytic assays, using cytosolic extracts. A 24-h exposure to 1 microM 5-FU in the H630 line resulted in a 3.1-fold increase in the total amount of TS, while in the 5-FU/IFN-gamma-treated cells TS remained unchanged from non-drug-treated control levels. Moreover, we found that free thymidylate synthase in the 5-FU/IFN-gamma-treated cells was significantly decreased, as compared to the cells treated with 5-FU alone. Incorporation of 5-FU into both the RNA and DNA fractions did not change with the addition of IFN-gamma. Accumulation of the fluoropyrimidine metabolites 5-fluoro-2'-deoxyuridine-5'-monophosphate and 5-fluorouridine-5'-triphosphate remained the same for 5-FU alone and the combination treatment. These findings suggest that acute TS induction by 5-FU may provide an important mechanism by which human colon carcinoma cells express decreased sensitivity to 5-FU and that IFN-gamma can reverse the development of resistance to 5-FU in the H630 line by inhibiting the overexpression of TS that results from 5-FU exposure. These studies contribute to a growing understanding of the complex interaction between 5-FU and IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697502

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex.

Authors:  E Chu; S M Copur; J Ju; T M Chen; S Khleif; D M Voeller; N Mizunuma; M Patel; G F Maley; F Maley; C J Allegra
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

2.  Characterization of a cis-acting regulatory element in the protein coding region of thymidylate synthase mRNA.

Authors:  X Lin; L A Parsels; D M Voeller; C J Allegra; G F Maley; F Maley; E Chu
Journal:  Nucleic Acids Res       Date:  2000-03-15       Impact factor: 16.971

3.  Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells.

Authors:  P J Ferguson; J M DeMoor; M D Vincent; J Koropatnick
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 4.  Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance.

Authors:  G J Sewell
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

Review 5.  Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.

Authors:  R Horowitz; E L Schwartz; S Wadler
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

6.  Inhibition of dihydropyrimidine dehydrogenase by alpha-interferon: experimental data on human tumor cell lines.

Authors:  G Milano; J L Fischel; M C Etienne; N Renée; P Formento; A Thyss; M H Gaspard; L Thill; D Cupissol
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase.

Authors:  E Chu; D M Koeller; J L Casey; J C Drake; B A Chabner; P C Elwood; S Zinn; C J Allegra
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

Review 8.  Potential uses of interferon alpha 2 as adjuvant therapy in cancer.

Authors:  S S Agarwala; J M Kirkwood
Journal:  Ann Surg Oncol       Date:  1995-07       Impact factor: 5.344

9.  Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.

Authors:  E E Vokes; S M O'Brien; N J Vogelzang; R L Schilsky; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.

Authors:  C J Punt; P H de Mulder; J T Burghouts; D J Wagener
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.